Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbal Products Firm Sues To Teach FTC A History Lesson

This article was originally published in The Tan Sheet

Executive Summary

Native Essence Herb Co. says federal advertising guidelines essentially prevent telling consumers about the history of herbal products

You may also be interested in...



FLAVORx Hopes A Spray-Full Of Pill Glide Helps The Medicine Go Down

FLAVORx designed its flavored Pill Glide Swallowing Sprayto help consumers take difficult-to-swallow or unpleasant-tasting pills

FLAVORx Hopes A Spray-Full Of Pill Glide Helps The Medicine Go Down

FLAVORx designed its flavored Pill Glide Swallowing Sprayto help consumers take difficult-to-swallow or unpleasant-tasting pills

Senate Exempts Supplements From Redundant Regs; Suppliers Left Hanging

Food safety reform bill does not similarly exclude ingredient suppliers, who would presumably be subject to hazard analysis and critical control point-like rules.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel